We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
20/10/2015 15:25 | People losing patience and selling. Another RNS would be timely.(I still hold) | doodlebug4 | |
28/9/2015 16:46 | I take it you have the PR role :) | pegasus59 | |
28/9/2015 16:22 | They should employ you as a marketing consultant.:-) | doodlebug4 | |
28/9/2015 15:54 | I think COS will announce it in the morning.Hope i didnt steal their thunder. Sorry Stewart | pegasus59 | |
28/9/2015 15:51 | Good news, thank you for that info pegasus. | doodlebug4 | |
28/9/2015 13:05 | Panmure Gordon reiterates BUY - target price 18p | doodlebug4 | |
28/9/2015 07:01 | Collagen Solutions PLC 28 September 2015 Collagen Solutions Plc (the "Company" or the "Group") Supply Agreement with Yucel Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that its subsidiary Collagen Solutions Inc. has signed a supply agreement with Turkish medical device company Yücel Medikal Ltd (Yucel) This supply agreement covers the provision of collagen materials and support services for use in Yucel's product Lyocoll which is currently on sale in Turkey. Lyocoll is a local haemostatic used in all types of surgery to control capillary and venous bleeding as well as oozing where the conventional methods are impractical and ineffective. Commenting on the agreement Dr Stewart White, CEO of Collagen Solutions, said: "Collagen Solutions is pleased to have signed another supply agreement with our valued customer Yucel to provide materials for their haemostatic product Lyocoll. This supply agreement further demonstrates the range of products that our medical grade collagens are suitable for and the global nature of our reach." Senol Yucel, CEO of Yucel added: "Consistency of product and continuity of supply are two very important factors for us and we have carried out a thorough review of the capabilities of Collagen Solutions to deliver the specific collagen that we require for Lyocoll. We are therefore pleased to be able to sign this agreement with a company which we can trust to deliver a quality product for us." | doodlebug4 | |
22/9/2015 06:27 | Collagen Solutions PLC 22 September 2015 22 September 2015 Collagen Solutions Plc Awarded Medical Research Scotland Ph.D. Studentship Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has been awarded a Medical Research Scotland Ph.D. studentship in partnership with the University of Strathclyde. The project titled "Improving control over the mechanical and transport properties of collagen-based scaffolds for tissue engineering and regenerative medicine" will be delivered by the University of Strathclyde and Collagen Solutions plc and is one of only 13 four-year PhD Studentships funded by Medical Research Scotland this year. (hxxp://www.medicalr Collagen, the most widely used matrix for Tissue Engineering and Regenerative Medicine, undergoes a constant process of remodelling in the body, and the balance of its degradation by the cells of the body with new collagen synthesis determines its strength and integrity over time. Thus, there is a clear need for safe and effective methods to control the rate implanted collagen is degraded. Using a cell culture model researchers at the University of Strathclyde have discovered that, by treating collagen with existing clinically-approved drugs, they are able to slow down the rate at which collagen scaffolds are degraded. This project will provide further insight into the potential for a wider range of drugs of this class to manipulate collagen degradation profiles. Methods for characterising the mechanical properties of collagen-based scaffolds will also be improved. Working with staff from Collagen Solutions, the data will ultimately be used to design novel collagen-based products for the medical devices market and regenerative medicine markets. Dr Stewart White, Chief Executive Officer of Collagen Solutions plc said: "This studentship is further recognition of the expertise that Collagen Solutions has in the development and manufacture of a wide range of medical grade collagen based products for use in novel regenerative medicine products. The rapid application of new methods for the design and preservation of novel collagen scaffolds will generate applications for collagen materials where our know-how can be applied to and commercialised with significant benefits for patients." | doodlebug4 | |
17/9/2015 20:28 | Me too... exciting stuff.. from lots of angles | jacobjohn7 | |
16/9/2015 07:51 | doodlebug im happy to sit and watch over the next few years.Good info and steady news flow. | pegasus59 | |
16/9/2015 07:48 | More good news pegasus. Panmure Gordon may soon be upping their target price. | doodlebug4 | |
16/9/2015 06:17 | That speculative buy is looking better everyday.Another good news story with Histogenics | pegasus59 | |
15/9/2015 13:39 | Update today from Beaufort Securities: Collagen Solutions (LON:COS) – Speculative Buy Yesterday, Collagen Solutions (Collagen) informed that it has acquired all the assets and intellectual property rights of ChondroMimetic from Orthomimetics Limited (OL) and Cambridge Enterprise Limited (CEL). The company would issue 869,900 ordinary shares to fund this acquisition. Collagen has already issued half of the shares, with the remaining payable on completion. Further, Collagen mentioned that it would pay certain royalty on sales of the product to OL and CEL. The new products received from the contract would be transferred to a wholly owned subsidiary which will take care of the in-house manufacturing and registrations of products. ChondroMimetic is a collagen based implant for treating small osteochondral, chondral and subchondral defects, with total estimated target market size of over US$500m. Our view: The aforementioned update is in line with Collagen’s plan to expand its market in collagen related products. The deal will also provide Collagen access to a number of patents related to collagen-based bioactive materials held by OL and CEL. Newly acquired products help in structural repair of bones and joints along with delivering biological and therapeutic agents, which in turn may substantially reduce the cost of joint replacement. Earlier this month, Collagen’s long-term client NovaBone Products received approval for a novel device by the US Food & Drug Administration (FDA), which would be used in delivery of its collagen bone graft product MacroForm. Collagen is also set to benefit from this. Furthermore, Collagen has been selected to participate in a new research project aimed at developing novel new treatments for the Parkinson’s disease, headed by the Centre for Research in Medical Devices (CÚRAM). The company joining such a valued consortium validated its brand name for developing and supplying high quality products. In view of company’s increasing market penetration and continuous efforts to expand its portfolio of services, we maintain a Speculative Buy rating on the stock | doodlebug4 | |
14/9/2015 07:21 | 08:01 14 Sep 2015 Collagen Solutions has acquired all the assets and related products of ChondroMimetic - an implant for treating small cartilage defects - which is estimated to have an addressable market of more than US$500mln. The purchase and the exclusive worldwide licence for the IP was made from Orthomimetics Limited and Cambridge Enterprise Ltd. In return, Collagen is to issue 869,900 ordinary shares, half of which have already been issued on completion, with the balance deferred over the next two years. Also, a single digit royalty is payable on future sales to both OL and CEL. Stewart White, the chief executive of Collagen Solutions, said: "Having established Collagen Solutions as the go to company for providing novel medical grade collagens, we were in a position to look at acquiring products that are collagen related.." "ChondroMimetic is an ideal first medical device acquisition as it brings us both an established product as well as access to a portfolio of additional IP we can exploit in the future." ChondroMimetic and its related products and IP will be transferred to a newly formed subsidiary of Collagen, which will be responsible for bringing the manufacture of the product in-house and gaining registrations so it can be sold in all significant territories around the World. Proactive Investors | doodlebug4 | |
14/9/2015 06:34 | RNS Number : 8953Y Collagen Solutions PLC 14 September 2015 Collagen Solutions Plc (the "Company" or "Collagen Solutions") Acquires all assets for ChondroMimetic and related products Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has acquired all of the assets and an exclusive worldwide licence for the associated intellectual property to ChondroMimetic from Orthomimetics Limited ("OL") and Cambridge Enterprise Limited ("CEL"). The consideration payable includes issuing 869,900 ordinary shares. 50% of the consideration is payable on completion, and 434,950 ordinary shares have been issued, with the balance deferred over the next two years. In addition a single digit royalty is payable on future sales of the product to both OL and CEL. ChondroMimetic is a collagen based implant for the treatment of small osteochondral (cartilage and underlying bone) defects and had previously received CE-mark approval for the treatment of small chondral and subchondral lesions. The addressable market is estimated to be in excess of US$500m. The deal for this product, which has been used in over 300 successful procedures, gives Collagen Solutions access to a portfolio of patents and patent applications covering a range of related collagen-based bioactive materials. These have the potential to revolutionise the regenerative medicine market for orthobiologics providing structural repair for bones and joints as well as the delivery of biological agents such as stem cells and other therapeutic agents. The ability to effectively repair joints rather than have to replace them will reduce the US$36bn cost to health services of joint replacements significantly. ChondroMimetic and its related products and IP will be transferred to a newly formed wholly owned subsidiary of Collagen Solutions. This subsidiary will be responsible for bringing the manufacture of the product in-house and gaining registrations for the product in order for it to be sold in all significant territories around the World. Commenting on the acquisition Stewart White, CEO of Collagen Solutions, said: "Having established Collagen Solutions as the go to Company for providing novel medical grade collagens, we were in a position to look at acquiring products that are collagen related and would give us the opportunity to not only provide part of the product, but to add value through the manufacture, supply and commercialisation thereby retaining a greater proportion of the value of the product within Collagen Solutions. "ChondroMimetic is an ideal first medical device acquisition as it brings us both an established product as well as access to a portfolio of additional IP we can exploit in the future." Ian Harris, Company Director, of Orthomimetics added: "We are delighted to have reached this agreement with Collagen Solutions which has the resources and knowledge-base to see ChondroMimetic build on its early promise and create additional novel related products which will revolutionise the orthobiologics market." Application has been made for the 434,950 ordinary shares to be admitted to trading on AIM which is expected to occur on or around 18 September 2015. Following this issue of ordinary shares, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 171,403,815 ordinary shares. For a video of the ChondroMimetic procedure, please view: | doodlebug4 | |
11/9/2015 12:39 | Toddle off mike, you are a complete waste of space - not just on this thread, but on every thread you crawl all over. | doodlebug4 | |
11/9/2015 12:30 | Yooooooooooo tulip aka doodles aka jeremy jezza, COME ON STEP IT UP, this is not good enough. Your work effort here on this thread is pathetic. Forget the cricket get doing some research for COS or COL. | mike740 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |